Health utility of patients with Crohn’s disease and ulcerative colitis: a systematic review and meta-analysis

References

• Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365:1713–1725.
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet. 2012;380:1590–1605.
   PubMed Web of Science ®Google Scholar
• Pascual V, Dieli-Crimi R, López-Palacios N, et al. Inflammatory bowel disease and celiac disease: overlaps and differences. World J Gastroenterol. 2014 May 7;20(17):4846–4856.
   PubMed Web of Science ®Google Scholar
• Farmer RG, Easley KA, Farmer JM. Quality of life assessment by patients with inflammatory bowel disease. Cleve Clin J Med. 1992;59:35–42.
   PubMed Web of Science ®Google Scholar
• Casellas F, Arenas JI, Baudet JS, et al. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis. 2005 May;11(5):488–496.
   PubMed Web of Science ®Google Scholar
• Von Neumann J, Morgenstern O. Theory of games and economic behavior. 3rd ed. New York (NY): John Wiley; 1953.
   Google Scholar
• Roberge R, Berthelot JM, Wolfson M. The Health Utility Index: measuring health differences in Ontario by socioeconomic status. Statistics Canada, Cat. No. 82-003. Health Rep. 1995;7:2.
   Google Scholar
• Cost-Effectiveness Analysis Registry. Available from: https://research.tufts-nemc.org/cear4/Home.aspx
   Google Scholar
• Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Available from: http://www.prisma-statement.org
   Google Scholar
• Alrubaiy L, Cheung W-Y, Dodds P, et al. Development of a short questionnaire to assess the quality of life in Crohn’s disease and ulcerative colitis. J Crohns Colitis. 2015 Jan;9(1):66–76.
   PubMedGoogle Scholar
• Arseneau KO, Cohn SM, Cominelli F, et al. Cost-utility of initial medical management for Crohn’s disease perianal fistulae. Gastroenterology. 2001 Jun;120(7):1640–1656.
   PubMed Web of Science ®Google Scholar
• Arseneau KO, Sultan S, Provenzale DT, et al. Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis? Clin Gastroenterol Hepatol. 2006 Sep;4(9):1135–1142.
   PubMed Web of Science ®Google Scholar
• Benedini V, Caporaso N, Corazza GR, et al. Burden of Crohn’s disease: economics and quality of life aspects in Italy. Clinicoecon Clinicoecon Outcomes Res. 2012;4:209–218.
   PubMedGoogle Scholar
• Bodger K, Ormerod C, Shackcloth D, et al. Development and validation of a rapid, generic measure of disease control from the patient’s perspective: the IBD-control questionnaire. Gut. 2014 Jul;63(7):1092–1102.
   PubMed Web of Science ®Google Scholar
• Brown LK, Waljee AK, Higgins PD, et al. Proximity to disease and perception of utility: physicians’ vs patients’ assessment of treatment options for ulcerative colitis. Dis Colon Rectum. 2011 Dec;54(12):1529–1536.
   PubMed Web of Science ®Google Scholar
• Casellas F, López-Vivancos J, Badia X, et al. Impact of surgery for Crohn’s disease on health-related quality of life. Am Am J Gastroenterol. 2000 Jan;95(1):177–182.
   PubMed Web of Science ®Google Scholar
• Casellas F, Vivancos JL, Sampedro M, et al. Relevance of the phenotypic characteristics of Crohn’s disease in patient perception of health-related quality of life. Am J Gastroenterol. 2005 Dec;100(12):2737–2742.
   PubMed Web of Science ®Google Scholar
• Casellas F, Rodrigo L, Niño P, et al. Sustained improvement of health-related quality of life in Crohn’s disease patients treated with infliximab and azathioprine for 4 years. Inflamm Bowel Dis. 2007 Nov;13(11):1395–1400.
   PubMed Web of Science ®Google Scholar
• Casellas F, Barreiro De Acosta M, Iglesias M, et al. Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2012 Jul;24(7):762–769.
   PubMed Web of Science ®Google Scholar
• Gibson PR, Vaizey C, Black CM, et al. Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: a cross-sectional, observational study. J Crohns Colitis. 2014;8(7):598–606.
   Web of Science ®Google Scholar
• Gregor JC, McDonald JW, Klar N, et al. An evaluation of utility measurement in Crohn’s disease. Inflamm Bowel Dis. 1997 Winter;3(4):265–276.
   PubMed Web of Science ®Google Scholar
• Huamán JW, Casellas F, Borruel N, et al. Cutoff values of the inflammatory Bowel disease questionnaire to predict a normal health related quality of life. J Crohn’s Colitis. 2010 Dec;4(6):637–641.
   Google Scholar
• Irvine EJ. Quality of life in inflammatory bowel disease: biases and other factors affecting scores. Scand J Gastroenterol Suppl. 1995;208:136–140.
   PubMedGoogle Scholar
• Kennedy ED, Detsky AS, Llewellyn-Thomas HA, et al. Can the standard gamble be used to determine utilities for uncertain health states? An example using postoperative maintenance therapy in Crohn’s disease. Med Decis Making. 2000 Jan-Mar;20(1):72–78.
   PubMed Web of Science ®Google Scholar
• Kim ES, Cho KB, Park KS, et al. Predictive factors of impaired quality of life in Korean patients with inactive inflammatory Bowel disease association with functional gastrointestinal disorders and mood disorders. J Clin Gastroenterol. 2013;47:38–44.
   Web of Science ®Google Scholar
• Kuruvilla K, Osler T, Hyman NH. A comparison of the quality of life of ulcerative colitis patients after IPAA vs ileostomy. Dis Colon Rectum. 2012 Nov;55(11):1131–1137.
   PubMed Web of Science ®Google Scholar
• McLeod RS, Churchill DN, Lock AM, et al. Quality of life of patients with ulcerative colitis preoperatively and postoperatively. Gastroenterology. 1991 Nov;101(5):1307–1313.
   PubMed Web of Science ®Google Scholar
• Muir AJ, Edwards LJ, Sanders LL, et al. A prospective evaluation of health-related quality of life after ileal pouch anal anastomosis for ulcerative colitis. Am J Gastroenterol. 2001 May;96(5):1480–1485.
   PubMed Web of Science ®Google Scholar
• Poole CD, Connolly MP, Nielsen SK, et al. A comparison of physician-rated disease severity and patient reported outcomes in mild to moderately active ulcerative colitis. J Crohn’s Colitis. 2010 Sep;4(3):275–282.
   Google Scholar
• Priest VL, Begg EJ, Gardiner SJ, et al. Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomics. 2006;24(8):767–781.
   PubMed Web of Science ®Google Scholar
• Provenzale D, Shearin M, Phillips-Bute BG, et al. Health-related quality of life after ileoanal pull-through evaluation and assessment of new health status measures. Gastroenterology. 1997 Jul;113(1):7–14.
   PubMed Web of Science ®Google Scholar
• Richards DM, Hughes SA, Irving MH, et al. Patient quality of life after successful restorative proctocolectomy is normal. Colorectal Dis. 2001 Jul;3(4):223–226.
   PubMedGoogle Scholar
• Richardson G, Sculpher M, Kennedy A, et al. Is self-care a cost-effective use of resources? Evidence from a randomized trial in inflammatory bowel disease. J Health Serv Res Policy. 2006 Oct;11(4):225–230.
   PubMedGoogle Scholar
• Stark RG, Reitmeir P, Leidl R, et al. Validity, reliability, and responsiveness of the EQ-5D in inflammatory bowel disease in Germany. Inflamm Bowel Dis. 2010 Jan;16(1):42–51.
   PubMed Web of Science ®Google Scholar
• Tillinger W, Mittermaier C, Lochs H, et al. Health-related quality of life in patients with Crohn’s disease: influence of surgical operation–a prospective trial. Dig Dis Sci. 1999 May;44(5):932–938.
   PubMed Web of Science ®Google Scholar
• Tolkien Z, Pereira DI, Prassmayer L, et al. Dietary iron does not impact the quality of life of patients with quiescent ulcerative colitis: an observational study. Nutr J. 2013 Nov;23(12):152.
   Web of Science ®Google Scholar
• Waljee AK, Higgins PD, Waljee JF, et al. Perceived and actual quality of life with ulcerative colitis: a comparison of medically and surgically treated patients. Am J Gastroenterol. 2011 Apr;106(4):794–799.
   PubMed Web of Science ®Google Scholar
• Yu AP, Johnson S, Wang ST, et al. Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn’s disease. Pharmacoeconomics. 2009;27(7):609–621.
   PubMed Web of Science ®Google Scholar
• van der Have M, van der Aalst KS, Kaptein AA, et al. Determinants of health-related quality of life in Crohn’s disease: a systematic review and meta-analysis. J Crohns Colitis. 2014;8:93–106.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Coteur G, Tan S, et al. Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn’s disease. Am J Gastroenterol. 2009;104:1976–1983.
   PubMed Web of Science ®Google Scholar
• Prenzler A, Yen L, Mittendorf T, et al. Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine. BMC Health Serv Res. 2011 Jul;5(11):157.
   Web of Science ®Google Scholar
• Tsai HH, Punekar YS, Morris J, et al. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther. 2008 Nov 15;28(10):1230–1239.
   PubMed Web of Science ®Google Scholar
• Buxton MJ, Lacey LA, Feagan BG, et al. Mapping from disease-specific measures to utility: an analysis of the relationships between the Inflammatory Bowel Disease Questionnaire and Crohn’s Disease Activity Index in Crohn’s disease and measures of utility. Value Health. 2007 May-Jun;10(3):214–220.
   PubMed Web of Science ®Google Scholar
• Loftus EV Jr, Johnson SJ, Yu AP, et al. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn’s disease. Eur J Gastroenterol Hepatol. 2009 Nov;21(11):1302–1309.
   PubMed Web of Science ®Google Scholar